Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches

Murali, Reshma; Wanjari, Uddesh Ramesh; Mukherjee, Anirban Goutam; Gopalakrishnan, Abilash Valsala; Kannampuzha, Sandra; Namachivayam, Arunraj; Madhyastha, Harishkumar; Renu, Kaviyarasi; Ganesan, Raja

doi:10.3390/vaccines11020489

Cited by 4 publications

(4 citation statements)

References 231 publications

(254 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Technologies and computing instruments allow for a more detailed and comprehensive exploration of many metabolites in a single assessment, offering a wider perspective on disease mechanisms. Metabolomics has allowed the detailed investigation of kidney diseases by assessing related molecular pathways and has initiated the development of novel molecular diagnostic tools for nephrology [94,95].…”

Section: Kidney Diseasementioning

confidence: 99%

COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?

Camelo,

Zamora Obando,

Rocha

et al. 2024

Metabolites

View full text Add to dashboard Cite

The COVID-19 pandemic has brought about diverse impacts on the global population. Individuals with comorbidities were more susceptible to the severe symptoms caused by the virus. Within the crisis scenario, metabolomics represents a potential area of science capable of providing relevant information for understanding the metabolic pathways associated with the intricate interaction between the viral disease and previous comorbidities. This work aims to provide a comprehensive description of the scientific production pertaining to metabolomics within the specific context of COVID-19 and comorbidities, while highlighting promising areas for exploration by those interested in the subject. In this review, we highlighted the studies of metabolomics that indicated a variety of metabolites associated with comorbidities and COVID-19. Furthermore, we observed that the understanding of the metabolic processes involved between comorbidities and COVID-19 is limited due to the urgent need to report disease outcomes in individuals with comorbidities. The overlap of two or more comorbidities associated with the severity of COVID-19 hinders the comprehension of the significance of each condition. Most identified studies are observational, with a restricted number of patients, due to challenges in sample collection amidst the emergent situation.

show abstract

Section: Kidney Diseasementioning

confidence: 99%

COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?

Camelo,

Zamora Obando,

Rocha

et al. 2024

Metabolites

View full text Add to dashboard Cite

show abstract

“…A meta-analysis ( 8 ) found that 4.5% of all confirmed COVID-19 cases develop AKI, mostly prevalent in critical COVID-19 cases. More recent studies report the incidence of AKI to be 15%–25% and is specifically high in COVID-19 patients with pre-existing complications ( 9 ). Due to the high incidence of kidney damage during COVID-19, understanding precisely how SARS-CoV-2 affects the kidney during COVID-19 can help improve treatment of patients during hospitalization, as well as improve recovery of long-term COVID-19 or post-COVID-19 patients suffering from kidney complications.…”

Section: Introductionmentioning

confidence: 99%

“…As for the origin of AKI during COVID-19, many causal factors have been proposed, including hyper-coagulation, microangiopathy, rhabdomyolysis, endothelial activation, dysregulation of complement, and angiotensin-converting enzyme 2 (ACE2) pathway activation ( 9 , 10 ). In addition, the direct cytotoxic effect of viral infection has also been suggested as a cause of kidney damage.…”

Section: Introductionmentioning

confidence: 99%

Nucleocapsid protein accumulates in renal tubular epithelium of a post-COVID-19 patient

Grootemaat,

Wiersma,

van der Niet

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

In this study, we investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins and virus particles can be detected (i) in post-mortem kidney of fatal coronavirus disease 2019 (COVID-19) patients and (ii) in renal biopsy of patients suffering from kidney failure months after combating a SARS-CoV-2 infection. Using fluorescence microscopy, antibodies against viral proteins [nucleocapsid, membrane (M), non-structural proteins (nsp) 3, 4, and 13] and double-stranded RNA (dsRNA) were validated on SARS-CoV-2-infected Vero cells. dsRNA was detected in lipid-filled electron-lucent (white) compartments in SARS-CoV-2-producing cells. In the kidney of a patient with acute kidney failure, accumulation of SARS-CoV-2 nucleocapsid N protein was detected in tubular epithelium. In contrast, none of the other viral proteins (M, nsp3, 4, 13) nor dsRNA was detected in these regions, suggesting that no viral replication takes place in the kidney of these patients. High-resolution immunoelectron microscopy demonstrated N protein accumulation in Golgi-like structures but absence of intracellular virus particles. The presence of the N protein in Golgi-like structures in kidney of patients suggests that this protein may have an unforeseen role in post-COVID-19 renal complications. IMPORTANCE Even though the coronavirus disease 2019 (COVID-19) pandemic is slowly developing into a conventional infectious disease, the long-term effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection are still not well understood. One of the problems is that many COVID-19 cases develop acute kidney injuries. Still, it is heavily debated whether SARS-CoV-2 virus enters and actively replicates in kidney tissue and if SARS-CoV-2 virus particles can be detected in kidney during or post-infection. Here, we demonstrated that nucleocapsid N protein was detected in kidney tubular epithelium of patients that already recovered form COVID-19. The presence of the abundantly produced N protein without signs of viral replication could have implications for the recurrence of kidney disease and have a continuing effect on the immune system.

show abstract

“…Metabolomic profiling can complement the lack of knowledge regarding the molecular mechanisms underlying clinical manifestations and pathogenesis of COVID-19. Consequently, several studies have employed metabolomic approaches to better understand the metabolic pathways involved in COVID-19 pathogenesis ( Ansone et al, 2021 ; Chen et al, 2022 ; Murali et al, 2023 ). Serum-based metabolomic studies in COVID-19 patients revealed altered glycolytic pathways as well as amino acid, lipid, and anaplerotic metabolism, suggesting an impact on energy pathways, inflammatory response, and oxidative stress, and confirming the systemic nature of the disease ( Kimhofer et al, 2020 ; Lorente et al, 2021 ; Shi et al, 2021 ; Valdés et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

A comparative NMR-based metabolomics study of lung parenchyma of severe COVID-19 patients

Hurtado,

López-Radcenco,

Izquierdo-García

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

COVID-19 was the most significant infectious-agent-related cause of death in the 2020-2021 period. On average, over 60% of those admitted to ICU facilities with this disease died across the globe. In severe cases, COVID-19 leads to respiratory and systemic compromise, including pneumonia-like symptoms, acute respiratory distress syndrome, and multiorgan failure. While the upper respiratory tract and lungs are the principal sites of infection and injury, most studies on the metabolic signatures in COVID-19 patients have been carried out on serum and plasma samples. In this report we attempt to characterize the metabolome of lung parenchyma extracts from fatal COVID-19 cases and compare them with that from other respiratory diseases. Our findings indicate that the metabolomic profiles from fatal COVID-19 and non-COVID-19 cases are markedly different, with the former being the result of increased lactate and amino acid metabolism, altered energy pathways, oxidative stress, and inflammatory response. Overall, these findings provide additional insights into the pathophysiology of COVID-19 that could lead to the development of targeted therapies for the treatment of severe cases of the disease, and further highlight the potential of metabolomic approaches in COVID-19 research.

show abstract

Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches

Cited by 4 publications

References 231 publications

COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?

COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?

Nucleocapsid protein accumulates in renal tubular epithelium of a post-COVID-19 patient

A comparative NMR-based metabolomics study of lung parenchyma of severe COVID-19 patients

Contact Info

Product

Resources

About